Patents Assigned to AltaThera Pharmaceuticals, LLC
  • Patent number: 11696902
    Abstract: This disclosure provides a method of safely and rapidly initiating or escalating oral sotalol therapy by administering an intravenous dosage of sotalol followed by oral sotalol twice daily.
    Type: Grant
    Filed: November 24, 2019
    Date of Patent: July 11, 2023
    Assignee: AltaThera Pharmaceuticals, LLC
    Inventors: John Somberg, Brandon Ira Kashfian, Janos Molnar
  • Patent number: 11610660
    Abstract: The disclosure relates to a method which includes i) prompting input of: a creatinine clearance (CrCl) of a subject; whether the subject is being initiated or escalated on sotalol hydrochloride; an amount of an oral target dosage of sotalol hydrochloride for the subject; and optionally a projected start time for sotalol hydrochloride infusion; and ii) executing computer executable instructions to derive from a set of rules a sotalol hydrochloride dosing protocol for the subject based on the inputs. The disclosure also relates to systems and medical devices configured to perform one or more steps of the method, as well as a non-transitory computer-readable storage medium comprising computer-executable instructions or software stored thereon capable of performing one or more steps of the method.
    Type: Grant
    Filed: December 31, 2021
    Date of Patent: March 21, 2023
    Assignee: AltaThera Pharmaceuticals LLC
    Inventors: Jodi Devlin, Brandon Ira Kashfian
  • Patent number: 11344518
    Abstract: The present invention provides a novel method of converting AF and monitoring normal sinus rhythm using an initial IV dose of sotalol followed by oral sotalol maintenance therapy. This method provides a method of acute assessment of QTc prolongation to determine the safety of chronic oral sotalol therapy and reduces the hospitalization stay required for conversion and sotalol initiation.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: May 31, 2022
    Assignee: AltaThera Pharmaceuticals LLC
    Inventor: John Somberg
  • Patent number: 10512620
    Abstract: This disclosure provides method of safely and efficaciously treating or preventing atrial fibrillation, atrial flutter, or a combination thereof via rapid intravenous introduction of sotalol hydrochloride to a subject in need thereof.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: December 24, 2019
    Assignee: AltaThera Pharmaceuticals, LLC
    Inventors: John Charin Somberg, Brandon Ira Kashfian, Janos Molnar